Hyperthermic isolated limb perfusion increases circulating levels of inflammatory cytokines.
Hyperthermic isolated limb perfusion is an established method of treatment for regionally advanced melanoma. Recent studies suggest that exogenously administered cytokines potentiate tumor response in patients with in-transit melanoma. We hypothesized that isolated limb perfusion induces an immunogenic response characterized by increased circulating levels of cytokines in the pump circuit, potentially contributing to the antitumor effect. We obtained blood samples from the perfusion circuit and systemic circulation at various intervals from patients undergoing isolated chemotherapeutic perfusion for melanoma. Samples were analyzed for serum cytokine profiles by enzyme-linked immunosorbent assay. When compared with baseline values, significant increases in serum levels of interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor (TNF) occurred within the perfusion circuit during isolated limb perfusion (P < 0.05). In addition, there was a corresponding increase in IL-8 within the systemic circulation at the 60-min interval (P < 0.05), suggesting some degree of leakage from the isolated circuit due to the extremely high levels of IL-8 in the perfusion circuit. A transient but insignificant decrease in circulating levels of neutrophils was also observed during the perfusion process, which may be attributed to margination. Increased levels of cytokines IL-6, IL-8, and TNF occurred within the isolated circuit during hyperthermic limb perfusion and may contribute to tumor response seen in patients treated with isolated limb perfusion.
Quinn
T D
TD
Department of Surgery, University of Louisville, School of Medicine, KY 40292, USA.
Polk
H C
HC
Edwards
M J
MJ
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D016207:Cytokines / Q000097:blood*; D003609:Dactinomycin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005121:Extremities; D006801:Humans; D006979:Hyperthermia, Induced; D007249:Inflammation / Q000097:blood / Q000209:etiology; D007260:Infusion Pumps; D008466:Mechlorethamine / Q000008:administration & dosage; D008545:Melanoma / Q000097:blood / Q000628:therapy
D016207:Cytokines; D003609:Dactinomycin; D008466:Mechlorethamine